CIPLA1,374.00

Cipla Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.11L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations25,774.127,547.628,162.628,324.4
Other Income746.6861.9882.0834.4
Total Income26,520.728,409.529,044.629,158.8
Expenses
+ Cost of Materials Consumed5,220.55,409.65,841.65,729.2
+ Purchases of Stock-in-Trade3,536.03,851.54,451.44,678.1
+ Changes in Inventories63.0-332.1-743.9-361.7
+ Employee Benefit Expense4,310.04,832.85,366.35,551.4
+ Finance Costs89.962.054.457.4
+ Depreciation & Amortisation1,051.01,107.01,211.01,262.5
+ Other Expenses6,353.46,657.97,364.37,430.3
Total Expenses20,623.921,588.723,545.124,347.2
EBITDA6,291.17,127.95,882.95,297.1
EBIT5,240.06,021.04,671.94,034.6
Profit
PBT before Exceptional Items5,896.76,820.85,499.54,811.5
+ Exceptional Items-194.80.0-275.9-275.9
Pretax Income5,701.96,820.85,223.64,535.6
+ Current Tax1,696.81,708.41,441.01,304.2
+ Deferred Tax-150.3-178.6-87.1-133.4
Tax Expense1,546.61,529.81,353.81,170.8
+ Share of Associates & JVs-1.6-21.9-8.1-9.2
Net Income4,153.75,269.23,861.73,355.7
+ Net Income — Continuing Ops4,155.35,291.13,869.83,364.8
+ Other Comprehensive Income-120.6218.7687.7800.4
Total Comprehensive Income4,033.15,487.94,549.54,156.1
Net Income to Common4,121.65,272.53,879.23,370.7
Minority Interest32.2-3.3-17.5-15.0
Per Share
Basic EPS51.0565.2948.0341.74
Diluted EPS51.0165.2448.0041.70
Other Comprehensive Income — detail
+ Other Comprehensive Income218.7687.7800.4
+ Items NOT to be Reclassified to P&L-88.6-66.1-188.9-156.1
+ Tax on Items NOT to be Reclassified-9.9-2.16.2
+ Tax on Items NOT to be Reclassified — alt tag-27.7
+ Items to be Reclassified to P&L-58.6276.2828.1930.8
+ Tax on Items to be Reclassified1.3-46.5-31.9
+ Tax on Items to be Reclassified — alt tag1.1
Comprehensive Income — Owners of Parent3,997.75,489.54,567.94,171.7
Comprehensive Income — Non-controlling Interests35.4-1.6-18.4-15.7
Per Share — as-filed variants
Basic EPS — Continuing Operations51.0565.2948.0341.74
Diluted EPS — Continuing Operations51.0165.2448.0041.70
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit16,954.518,618.618,613.518,278.8
Gross Margin %65.7867.5966.0964.53
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)5,896.76,820.85,499.54,811.5
− Exceptional Items (reconciliation)-194.80.0-275.9-275.9
Net Income Adj (tax-effected)4,295.75,269.24,066.13,560.4
EPS Adj52.7965.2950.5744.29
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital161.5161.5161.6161.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.